Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Hiba EL Masri, Treasure M McGuire, Mieke L van Driel, Helen Benham & Samantha A Hollingworth. (2022) Dynamics of Patient-Based Benefit-Risk Assessment of Medicines in Chronic Diseases: A Systematic Review. Patient Preference and Adherence 16, pages 2609-2637.
Read now
Read now
Laurence Ball-King. (2022) Benefit-risk assessment: balancing the benefits and risks of leisure. World Leisure Journal 64:4, pages 383-398.
Read now
Read now
Stephan Schug, Esther Pogatzki-Zahn, Lawrence D Phillips, Margaret Noyes Essex, Feng Xia, Alison J Reader & Robert Pawinski. (2020) Multi-Criteria Decision Analysis to Develop an Efficacy-Safety Profile of Parenteral Analgesics Used in the Treatment of Postoperative Pain. Journal of Pain Research 13, pages 1969-1977.
Read now
Read now
Majed S Al Yami, Sawsan Kurdi & Ivo Abraham. (2018) Direct oral anticoagulants for extended thromboprophylaxis in medically ill patients: meta-analysis and risk/benefit assessment. Journal of Blood Medicine 9, pages 25-34.
Read now
Read now
Diogo Mendes, Carlos Alves & Francisco Batel Marques. (2016) Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons. Expert Opinion on Drug Safety 15:10, pages 1301-1312.
Read now
Read now
Articles from other publishers (29)
Kunle Rotimi, Babatunde Fagbemi, Taiwo Ibinaiye, Jimmy Aiden, Victor Gabriel, Chrysantus Dabes, Tapshak Kyeshir, Daniel Oguche, Omolola Obayemi, Aminu Biambo, Andrew Okwulu & Adaeze Aidenagbon. (2023) Spontaneous adverse drug reaction reporting during the seasonal malaria chemoprevention campaign in 2022. Bulletin of the National Research Centre 47:1.
Crossref
Crossref
Marija Guleva, Zorica Naumovska, Aleksandra Kapedanovska Nestorovska, Angela Mircheska-Janevska & Ankica Gestakovska. (2022) Risk management strategies and implementation of risk minimization measures for medicinal products. Macedonian Pharmaceutical Bulletin 68:03, pages 499-500.
Crossref
Crossref
Yulia Y. Orlova, Sandhya Mehla & Abigail L. Chua. (2022) Drug Safety in Episodic Migraine Management in Adults Part 1: Acute Treatments. Current Pain and Headache Reports 26:7, pages 481-492.
Crossref
Crossref
Matías Eduardo Díaz Crescitelli, Mark Hayter, Giovanna Artioli, Leopoldo Sarli & Luca Ghirotto. (2022) Relational dynamics involved in therapeutic discordance among prescribers and patients: A Grounded Theory study. Patient Education and Counseling 105:1, pages 233-242.
Crossref
Crossref
Charles Savona-Ventura & Yvonne Savona-Ventura. 2021. The EBCOG Postgraduate Textbook of Obstetrics & Gynaecology. The EBCOG Postgraduate Textbook of Obstetrics & Gynaecology
30
37
.
Donia Kharbouch, Houda Sefiani, Zineb Nabih, Sanou Khô Coulibaly, Tidiane Diallo, Abdelmajid Soulaymani, Abdelrhani Mokhtari & Rachida Soulaymani Bencheikh. (2021) Adverse drug reactions of anti-infective drugs for systemic use in Morocco: Pharmaco-Epidemiological study 2008-2016. E3S Web of Conferences 319, pages 01048.
Crossref
Crossref
Pushpraj Prafulla Gawai . (2020) Overview of important methods used for causality assessment of adverse drug events in pharmacovigilance. Journal of Pharmacovigilance and Drug Research 1:2, pages 6-12.
Crossref
Crossref
Elisa Giubilato, Virginia Cazzagon, Mónica J. B. Amorim, Magda Blosi, Jacques Bouillard, Hans Bouwmeester, Anna Luisa Costa, Bengt Fadeel, Teresa F. Fernandes, Carlos Fito, Marina Hauser, Antonio Marcomini, Bernd Nowack, Lisa Pizzol, Leagh Powell, Adriele Prina-Mello, Haralambos Sarimveis, Janeck James Scott-Fordsmand, Elena Semenzin, Burkhard Stahlmecke, Vicki Stone, Alexis Vignes, Terry Wilkins, Alex Zabeo, Lang Tran & Danail Hristozov. (2020) Risk Management Framework for Nano-Biomaterials Used in Medical Devices and Advanced Therapy Medicinal Products. Materials 13:20, pages 4532.
Crossref
Crossref
Rachel J. Tyson, Christine C. Park, J. Robert Powell, J. Herbert Patterson, Daniel Weiner, Paul B. Watkins & Daniel Gonzalez. (2020) Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables. Frontiers in Pharmacology 11.
Crossref
Crossref
Paweł Grieb. 2019. Handbook of Nutrition, Diet, and the Eye. Handbook of Nutrition, Diet, and the Eye
585
603
.
Anum Saqib, Muhammad Rehan Sarwar, Muhammad Sarfraz & Sadia Iftikhar. (2018) Causality and preventability assessment of adverse drug events of antibiotics among inpatients having different lengths of hospital stay: a multicenter, cross-sectional study in Lahore, Pakistan. BMC Pharmacology and Toxicology 19:1.
Crossref
Crossref
Jérémy Lambert, Michael Chekroun, Hélène Gilet, Catherine Acquadro & Benoit Arnould. (2018) Assessing patients’ acceptance of their medication to reveal unmet needs: results from a large multi-diseases study using a patient online community. Health and Quality of Life Outcomes 16:1.
Crossref
Crossref
Shivangi Agarwal, Ekta Verma, Vivek Kumar, Namrita Lall, Samaresh Sau, Arun K. Iyer & Sushil K. Kashaw. (2018) An integrated computational approach of molecular dynamics simulations, receptor binding studies and pharmacophore mapping analysis in search of potent inhibitors against tuberculosis. Journal of Molecular Graphics and Modelling 83, pages 17-32.
Crossref
Crossref
Timothy M. Wright. 2017. Scleroderma. Scleroderma
595
601
.
D. D. Ebert, L. Donkin, G. Andersson, G. Andrews, T. Berger, P. Carlbring, A. Rozenthal, I. Choi, J. A. C. Laferton, R. Johansson, A. Kleiboer, A. Lange, D. Lehr, J. A. Reins, B. Funk, J. Newby, S. Perini, H. Riper, J. Ruwaard, L. Sheeber, F. J. Snoek, N. Titov, B. Ünlü Ince, K. van Bastelaar, K. Vernmark, A. van Straten, L. Warmerdam, N. Salsman & P. Cuijpers. (2016) Does Internet-based guided-self-help for depression cause harm? An individual participant data meta-analysis on deterioration rates and its moderators in randomized controlled trials. Psychological Medicine 46:13, pages 2679-2693.
Crossref
Crossref
Axel C. Mühlbacher, Christin Juhnke, Andrea R. Beyer & Sarah Garner. (2016) Patient-Focused Benefit-Risk Analysis to Inform Regulatory Decisions: The European Union Perspective. Value in Health 19:6, pages 734-740.
Crossref
Crossref
Lateef M. Khan, Sameer E. Al-Harthi, Abdel-Moneim M. Osman, Mai A. Alim A. Sattar & Ahmed S. Ali. (2016) Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactions. Saudi Pharmaceutical Journal 24:4, pages 485-493.
Crossref
Crossref
Pia Osterlund, Halfdan Sorbye, Per Pfeiffer, Anders Johnsson, Filipe Rodrigues & Gianluca Furneri. (2016) Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries. Journal of Cancer Policy 7, pages 12-22.
Crossref
Crossref
Diogo Mendes, Carlos Alves & Francisco Batel‐Marques. (2015) Number needed to harm in the post‐marketing safety evaluation: results for rosiglitazone and pioglitazone. Pharmacoepidemiology and Drug Safety 24:12, pages 1259-1270.
Crossref
Crossref
Francesco Bellanti, Rob C. van Wijk, Meindert Danhof & Oscar Della Pasqua. (2015) Integration of PKPD relationships into benefit–risk analysis. British Journal of Clinical Pharmacology 80:5, pages 979-991.
Crossref
Crossref
Stephanie Seremetis, Roshni Kulkarni, Antoine Regnault & Elena Santagostino. (2015) Turoctocog alfa in the treatment of individuals with hemophilia A: review of quality of life data collected in Phase III trials. Clinical Investigation 5:9, pages 755-766.
Crossref
Crossref
Stuart McCarthy. (2015) Malaria Prevention, Mefloquine Neurotoxicity, Neuropsychiatric Illness, and Risk-Benefit Analysis in the Australian Defence Force. Journal of Parasitology Research 2015, pages 1-23.
Crossref
Crossref
Hanfried Helmchen. 2015. Handbook of Neuroethics. Handbook of Neuroethics
907
927
.
Shahrul Mt‐Isa, Christine E. Hallgreen, Nan Wang, Torbjörn Callréus, Georgy Genov, Ian Hirsch, Stephen F. Hobbiger, Kimberley S. Hockley, Davide Luciani, Lawrence D. Phillips, George Quartey, Sinan B. Sarac, Isabelle Stoeckert, Ioanna Tzoulaki, Alain Micaleff & Deborah Ashby. (2014) Balancing benefit and risk of medicines: a systematic review and classification of available methodologies. Pharmacoepidemiology and Drug Safety 23:7, pages 667-678.
Crossref
Crossref
Alexander Rozental, Gerhard Andersson, Johanna Boettcher, David Daniel Ebert, Pim Cuijpers, Christine Knaevelsrud, Brjánn Ljótsson, Viktor Kaldo, Nickolai Titov & Per Carlbring. (2014) Consensus statement on defining and measuring negative effects of Internet interventions. Internet Interventions 1:1, pages 12-19.
Crossref
Crossref
Joachim Y. Doua & Jean‐Pierre Van Geertruyden. (2013)
Registering medicines for low‐income countries: how suitable are the stringent review procedures of the World Health Organisation, the
US
Food and Drug Administration and the European Medicines Agency?
. Tropical Medicine & International Health 19:1, pages 23-36.
Crossref
Crossref
Karmen Stankov, Ana Sabo & Momir Mikov. (2012) Pharmacogenetic Biomarkers as Tools for Pharmacoepidemiology of Severe Adverse Drug Reactions. Drug Development Research 74:1, pages 1-14.
Crossref
Crossref
Hanfried Helmchen. 2013. Ethik psychiatrischer Forschung. Ethik psychiatrischer Forschung
39
56
.
Sergi Mas, Adrián LLerena, Jerónimo Saíz, Miquel Bernardo & Amalia Lafuente. (2012) Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. Pharmacogenomics 13:15, pages 1773-1782.
Crossref
Crossref